CODXDiagnostics•prnewswire•
Co-Diagnostics, Inc. Performs Analysis of Chikungunya Co-Primers® to Confirm Reactivity Against Known Virus Strains
Sentiment:Positive (70)
Summary
(NASDAQ:CODX) SALT LAKE CITY, Sept. 11, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has performed an in silico analysis of...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 11, 2025 by prnewswire